[Lipid metabolism abnormalities in Chronic Kidney Disease]

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Lipidology

Background:

• Chronic kidney disease (CKD) is associated with profound lipoprotein metabolism abnormalities.
• These alterations begin early in the disease and worsen as renal function declines.
• Standard lipid profiles may not capture these complex changes, masking increased cardiovascular risk.

Purpose of the Study:

• To elucidate the qualitative and quantitative lipoprotein abnormalities in chronic kidney disease.
• To understand the contribution of these lipid alterations to the high rate of atherosclerotic events in CKD patients.
• To compare the lipid profile in CKD with conditions like metabolic syndrome and type 2 diabetes.

Main Methods:

• Analysis of apolipoproteins, lipid transfer proteins, lipolytic enzymes, and lipoprotein receptors in CKD patients.
• Assessment of lipoprotein particle size and density, including small dense LDL.
• Evaluation of lipoprotein(a) levels and HDL cholesterol functionality.

Main Results:

• CKD is characterized by increased triglycerides and decreased high-density lipoprotein (HDL) cholesterol.
• Progressive accumulation of atherogenic small dense low-density lipoprotein (LDL) particles occurs.
• Patients with nephrotic syndrome exhibit a markedly elevated atherogenic profile, including increased VLDL, LDL, IDL, and lipoprotein(a).
• Qualitative abnormalities like increased VLDL/IDL cholesterol, oxidized LDL, and dysfunctional HDL are prevalent.

Conclusions:

• CKD patients exhibit a pro-atherogenic lipid profile, contributing to high cardiovascular event rates.
• Lipid abnormalities in CKD share features with metabolic syndrome and type 2 diabetes, exacerbating insulin resistance.
• Standard lipid measurements may underestimate cardiovascular risk in CKD due to uncaptured qualitative changes.